Loading…
Loading…
Sentiment · FY2026 Q1
| Analyst | Firm | Questions | ChallengePercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|---|
| Lisa Gill | JPMorgan | 7 | 14% |
| Lance Wilkes | Bernstein | 6 | 0% |
| Andy Mok | Barclays | 6 | 17% |
| A.J. Rice | UBS | 6 | 0% |
| Justin Lake | Wolfe Research | 6 | 50% |
| George Hill | Deutsche Bank | 6 | 0% |
| Erin Wright | Morgan Stanley | 6 | 0% |
| Josh Raskin | Nephron Research | 5 | 20% |
| Dave Windley | Jefferies | 5 | 40% |
| Ann Hynes | Mizuho Securities | 5 | 20% |
| Firm | Analysts | Questions | ChallengePercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|---|
| JPMorgan | 1 | 7 | 14% |
| TD Cowen | 2 | 6 | 0% |
| Bank of America | 2 | 6 | 50% |
| Deutsche Bank | 1 |
| 6 |
| 0% |
| Bernstein | 1 | 6 | 0% |
| Morgan Stanley | 1 | 6 | 0% |
| Barclays | 1 | 6 | 17% |
| UBS | 1 | 6 | 0% |
Elevance reported Q1 2026 operating revenue of $49.5B, up 1.5%, with adjusted EPS of $12.58 as Medicaid cost trend actions gained early traction. Management raised FY2026 adjusted EPS guidance to at least $26.75 from at least $25.50, though approximately $1.00 of the $1.25 increase reflected nonrecurring investment valuation adjustments. The CMS risk adjustment data accrual reached $935M, and the commercial selling season pipeline stood at record levels.
Margin | Regulation Policy | Cost Pressure | Guidance Reliability | Competitive Dynamics | Subscriber Growth | Demand | Pricing | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 6 | 4 | 3 | 4 | 4 | 3 | 1 | 3 |
| 2025Q1 | 5 | 7 | 10 | 1 | 2 | 3 | 1 | |
| 2025Q2 | 7 | 7 | 7 | 3 | 1 | 1 | 2 | 2 |
| 2025Q3 | 4 | 7 | 4 | 3 | 3 | 4 | 1 | |
| 2025Q4 | 6 | 3 | 2 | 5 | 3 | 5 | 1 | 1 |
| 2026Q1 | 6 | 3 | 5 | 1 | 3 | 7 | 2 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Margin | 6 | 5 | 7 | 4 | 6 | 6 |
| Regulation Policy | 4 | 7 | 7 | 7 | 3 | 3 |
| Cost Pressure | 3 | 10 | 7 | 4 | 2 | 5 |
| Guidance Reliability | 4 | 1 | 3 | 3 | 5 | 1 |
| Competitive Dynamics | 4 | 2 | 1 | 3 | 3 | 3 |
| Subscriber Growth | 3 | 3 | 1 | 4 | 5 | |
| Demand | 1 | 1 | 2 | 1 | 7 | |
| Pricing | 3 | 2 | 1 | 1 | 2 |
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
ELV Elevance Health | 7 | +2.6% | |
| CI Cigna | 8 | +4.6% | |
| CNC Centene Corporation | 9 | +7.1% | |
| CVS CVS Health | 9 | +6.2% | |
| HUM Humana | 7 | +23.5% | |
| UNH UnitedHealth Group Incorporated | 7 | +2.0% |